These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 34946849)

  • 1. Epithelial-Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics.
    Chaves LP; Melo CM; Saggioro FP; Reis RBD; Squire JA
    Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
    Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H
    Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
    Shafran JS; Jafari N; Casey AN; Győrffy B; Denis GV
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):268-277. PubMed ID: 32690869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
    Colditz J; Rupf B; Maiwald C; Baniahmad A
    Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer.
    Li P; Yang R; Gao WQ
    Mol Cancer; 2014 Mar; 13():55. PubMed ID: 24618337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
    Nakazawa M; Kyprianou N
    J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2.
    Tsai YC; Chen WY; Abou-Kheir W; Zeng T; Yin JJ; Bahmad H; Lee YC; Liu YN
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1717-1727. PubMed ID: 29477409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth.
    Ramamurthy VP; Ramalingam S; Gediya LK; Njar VCO
    FEBS J; 2018 Mar; 285(6):1051-1063. PubMed ID: 29323792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
    Stoyanova T; Riedinger M; Lin S; Faltermeier CM; Smith BA; Zhang KX; Going CC; Goldstein AS; Lee JK; Drake JM; Rice MA; Hsu EC; Nowroozizadeh B; Castor B; Orellana SY; Blum SM; Cheng D; Pienta KJ; Reiter RE; Pitteri SJ; Huang J; Witte ON
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6457-E6466. PubMed ID: 27694579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression.
    Hu J; Tian J; Zhu S; Sun L; Yu J; Tian H; Dong Q; Luo Q; Jiang N; Niu Y; Shang Z
    Br J Cancer; 2018 Jan; 118(1):88-97. PubMed ID: 29123266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.
    Haider M; Zhang X; Coleman I; Ericson N; True LD; Lam HM; Brown LG; Ketchanji M; Nghiem B; Lakely B; Coleman R; Montgomery B; Lange PH; Roudier M; Higano CS; Bielas JH; Nelson PS; Vessella RL; Morrissey C
    Clin Exp Metastasis; 2016 Mar; 33(3):239-48. PubMed ID: 26667932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCAND1 Reverses Epithelial-to-Mesenchymal Transition (EMT) and Suppresses Prostate Cancer Growth and Migration.
    Eguchi T; Csizmadia E; Kawai H; Sheta M; Yoshida K; Prince TL; Wegiel B; Calderwood SK
    Cells; 2022 Dec; 11(24):. PubMed ID: 36552758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNAs and Prostate Cancer.
    Josson S; Chung LW; Gururajan M
    Adv Exp Med Biol; 2015; 889():105-18. PubMed ID: 26658999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of Wnt/β-catenin signaling pathway.
    Zhang X; Li H; Wang Y; Zhao H; Wang Z; Chan FL
    Cell Death Dis; 2024 Mar; 15(3):234. PubMed ID: 38531859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRKAR2B promotes prostate cancer metastasis by activating Wnt/β-catenin and inducing epithelial-mesenchymal transition.
    Sha J; Han Q; Chi C; Zhu Y; Pan J; Dong B; Huang Y; Xia W; Xue W
    J Cell Biochem; 2018 Sep; 119(9):7319-7327. PubMed ID: 29761841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMPRSS4 promotes cancer stem-like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1.
    Lee Y; Yoon J; Ko D; Yu M; Lee S; Kim S
    J Exp Clin Cancer Res; 2021 Nov; 40(1):372. PubMed ID: 34809669
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Fararjeh AS; Liu YN
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
    Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
    Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs and epithelial-mesenchymal transition in prostate cancer.
    Sekhon K; Bucay N; Majid S; Dahiya R; Saini S
    Oncotarget; 2016 Oct; 7(41):67597-67611. PubMed ID: 27588490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.